Vaccine Adjuvants Global Market Report 2024

Description

“Vaccine Adjuvants Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine adjuvants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The vaccine adjuvants market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product Type: Adjuvant Emulsions; Pathogen Components; Particulate Adjuvants; Combination Adjuvants; Other Product Types
2) By Route of Application: Human Vaccine Adjuvants; Veterinary Vaccine Adjuvants
3) By Route of Administration: Oral; Intramuscular; Intranasal; Subcutaneous; Intradermal
4) By Disease: Cancer; Infectious Diseases; Other Diseases
Companies Mentioned: GlaxoSmithKline Plc.; Novavax Inc.; SPI Pharma Inc.; Agenus Inc.; CSL Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Vaccine adjuvants refer to compounds or components included in vaccines to enhance the body's immune response to antigens that lack immunostimulatory capabilities, thereby creating a more robust immune reaction.

The primary categories of vaccine adjuvants include adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others, such as saponin-based adjuvants. Adjuvant emulsions are defined as mixtures of two or more typically immiscible liquids. These vaccine adjuvants are administered through various routes, including oral, intramuscular, intranasal, subcutaneous, and intradermal, in both human and veterinary settings. They are employed in the treatment of conditions such as cancer, infectious diseases, and other ailments, including zoonotic diseases.

The vaccine adjuvants market research report is one of a series of new reports from The Business Research Company that provides vaccine adjuvants market statistics, including the vaccine adjuvants industry's global market size, regional shares, competitors with a vaccine adjuvants market share, detailed vaccine adjuvants market segments, market trends, and opportunities, and any further data you may need to thrive in the vaccine adjuvants industry. This vaccine adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaccine adjuvants market size has grown strongly in recent years. It will grow from $1.77 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth observed in the historical period can be ascribed to the rise in vaccine development, the prevalence of infectious diseases, government initiatives, and immunization programs, substantial investments in research and development, as well as the globalization of vaccine distribution.

The vaccine adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be linked to preparedness for pandemics, the diversification of vaccine portfolios, global objectives for immunization, collaborative efforts and partnerships, and an emphasis on therapeutic vaccines. Prominent trends expected in the forecast period encompass progress in adjuvant technologies, a focus on enhancing immunogenicity, the use of combination adjuvants for heightened effectiveness, a demand for safer and well-tolerated adjuvants, as well as the development of personalized vaccines and adjuvants.

The anticipated growth of the vaccine adjuvants market is expected to be driven by the increasing prevalence of infectious diseases. Infectious diseases encompass infections caused by viruses, bacteria, fungi, or parasites. Vaccines play a crucial role in treating various infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis. As per the 2022 World Health Organization (WHO) report, approximately 10.6 million people globally were infected with tuberculosis in 2021, resulting in 1.6 million deaths, and 1.5 million individuals contracted HIV, with 650,000 losing their lives to it. Hence, the rising prevalence of infectious diseases is expected to be a key driver for the vaccine adjuvants market.

The expected growth of the vaccine adjuvants market is also anticipated to be fueled by the increasing funding for vaccine research activities. Vaccine research activities encompass comprehensive scientific endeavors focused on developing, testing, and enhancing vaccines to prevent infectious diseases. These research activities play a crucial role in identifying, testing, and optimizing potential adjuvant candidates derived from diverse sources, including natural products, synthetic compounds, and even bacteria or viruses. For example, in October 2023, the United States Department of Health and Human Services, a US-based provider of essential human services, announced Project NextGen, involving a $500 million investment to initiate the development of Phase 2b clinical trial plans and cutting-edge technologies for next-generation vaccination and treatment platforms. Consequently, the increasing funding for vaccine research activities is a driving force behind the growth of the vaccine adjuvants market.

The adoption of strategic partnerships is emerging as a significant trend in the vaccine adjuvants market, with numerous companies seeking collaborations to fortify their market positions. For example, in October 2021, Dynavax Technologies, a biotech company based in the US, joined forces with the U.S. Department of Defense to develop a plague vaccine enhanced with Dynavax's CpG 1018 adjuvant. Additionally, in September 2020, Valneva SE, a biotech company based in France, partnered with Dynavax, a US-based biotech company, to manufacture an adjuvant for the COVID-19 vaccine.

Prominent companies operating in the vaccine adjuvants market are concentrating on introducing innovative products, such as plant-based squalene, to gain a competitive advantage. Plant-based squalene, derived from the herbaceous plant amaranth (Amaranthus caudatus), offers a sustainable and cruelty-free alternative to traditional squalene obtained from shark liver oil. For instance, in December 2022, Evonik Industries AG, a specialty chemicals company based in Germany, launched PhytoSquene, a plant-based squalene utilized in adjuvants to enhance vaccine efficacy. This product has applications in adjuvants for parenteral vaccines, with potential expansion into other pharmaceutical and cosmetic uses. PhytoSquene addresses the needs of patients who, due to cultural or religious beliefs, cannot use products derived from animals.

In August 2022, GSK plc, a pharmaceutical and biotechnology company based in the UK, completed the acquisition of Affinivax Inc. for a deal amount of $3.3 billion. This acquisition bolsters GSK's strategy to establish a substantial portfolio of specialized novel drugs and vaccines. It includes a next-generation 24-valent pneumococcal vaccine adjuvant (AFX3772), based on the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax Inc. is a clinical-stage biopharmaceutical company based in the UK operating in the vaccine adjuvant market.

Major companies operating in the vaccine adjuvants market report are GlaxoSmithKline Plc., Novavax Inc., SPI Pharma Inc., Agenus Inc., CSL Limited, InvivoGen Limited., Brenntag Biosector A/S, Adjuvatis, Merck KGaA, Croda International Plc, Seppic Inc., OZ Biosciences, Avanti Polar Lipids Inc., Astellas Pharma Inc., Virometix AG, MPV Technologies Limited, Adjuvance Technologies Inc., Novartis AG, Vaxine Pty Ltd., SBI Biotech Co. Ltd., Statens Serum Institute, GSK Vaccines, VaxLiant LLC, VaxForm LLC, Serum Institute of India, Dynavax Technologies Corporation, Vaxcyte Inc., VBI Vaccines Inc., Medicago Inc., Aphios Corporation

North America was the largest region in the vaccine adjuvants market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vaccine adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vaccine adjuvants market consists of sales of adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and saponin-based adjuvants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12171

1. Executive Summary

2. Vaccine Adjuvants Market Characteristics

3. Vaccine Adjuvants Market Trends And Strategies

4. Vaccine Adjuvants Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Vaccine Adjuvants Market Size and Growth

5.1. Global Vaccine Adjuvants Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Vaccine Adjuvants Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Vaccine Adjuvants Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Vaccine Adjuvants Market Segmentation

6.1. Global Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Adjuvant Emulsions
Pathogen Components
Particulate Adjuvants
Combination Adjuvants
Other Product Types
6.2. Global Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Human Vaccine Adjuvants
Veterinary Vaccine Adjuvants
6.3. Global Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Intramuscular
Intranasal
Subcutaneous
Intradermal
6.4. Global Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cancer
Infectious Diseases
Other Diseases

7. Vaccine Adjuvants Market Regional And Country Analysis

7.1. Global Vaccine Adjuvants Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Vaccine Adjuvants Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Vaccine Adjuvants Market

8.1. Asia-Pacific Vaccine Adjuvants Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Vaccine Adjuvants Market

9.1. China Vaccine Adjuvants Market Overview
9.2. China Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Vaccine Adjuvants Market

10.1. India Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Vaccine Adjuvants Market

11.1. Japan Vaccine Adjuvants Market Overview
11.2. Japan Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Vaccine Adjuvants Market

12.1. Australia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Vaccine Adjuvants Market

13.1. Indonesia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Vaccine Adjuvants Market

14.1. South Korea Vaccine Adjuvants Market Overview
14.2. South Korea Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Vaccine Adjuvants Market

15.1. Western Europe Vaccine Adjuvants Market Overview
15.2. Western Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Vaccine Adjuvants Market

16.1. UK Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Vaccine Adjuvants Market

17.1. Germany Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Vaccine Adjuvants Market

18.1. France Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Vaccine Adjuvants Market

19.1. Italy Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Vaccine Adjuvants Market

20.1. Spain Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Vaccine Adjuvants Market

21.1. Eastern Europe Vaccine Adjuvants Market Overview
21.2. Eastern Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Vaccine Adjuvants Market

22.1. Russia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Vaccine Adjuvants Market

23.1. North America Vaccine Adjuvants Market Overview
23.2. North America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Vaccine Adjuvants Market

24.1. USA Vaccine Adjuvants Market Overview
24.2. USA Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Vaccine Adjuvants Market

25.1. Canada Vaccine Adjuvants Market Overview
25.2. Canada Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Vaccine Adjuvants Market

26.1. South America Vaccine Adjuvants Market Overview
26.2. South America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Vaccine Adjuvants Market

27.1. Brazil Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Vaccine Adjuvants Market

28.1. Middle East Vaccine Adjuvants Market Overview
28.2. Middle East Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Vaccine Adjuvants Market

29.1. Africa Vaccine Adjuvants Market Overview
29.2. Africa Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Vaccine Adjuvants Market Competitive Landscape And Company Profiles

30.1. Vaccine Adjuvants Market Competitive Landscape
30.2. Vaccine Adjuvants Market Company Profiles
- 30.2.1. GlaxoSmithKline Plc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novavax Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. SPI Pharma Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Agenus Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. CSL Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Vaccine Adjuvants Market Competitive Benchmarking

32. Global Vaccine Adjuvants Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Vaccine Adjuvants Market

34. Vaccine Adjuvants Market Future Outlook and Potential Analysis

34.1 Vaccine Adjuvants Market In 2028 - Countries Offering Most New Opportunities
34.2 Vaccine Adjuvants Market In 2028 - Segments Offering Most New Opportunities
34.3 Vaccine Adjuvants Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer